News >

Lung-MAP Trial Expands to Include All Patients With NSCLC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 30, 2019

Vali Papadimitrakopoulou, MD

Vali Papadimitrakopoulou, MD

The Lung Cancer Master Protocol (Lung-MAP), known as the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), has expanded to include patients with all types of non–small cell lung cancers (NSCLC), according to SWOG, the organization that manages the trial program.1

 

References

  1. LUNG-MAP Precision Medicine Trial Expands To Include More Patients. Lung Cancer Master Protocol. Published January 29, 2019. https://bit.ly/2HD4GLf. Accessed January 29, 2019.
  2. Herbst RS, Gandara DR, Hirsch FR, et al. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015;21(7). doi: 10.1158/1078-0432.CCR-13-3473.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x